Search Results - "Aguilar, E. Aranda"

Assessment and treatment of breakthrough cancer pain in Spain: A self-audit study by Lopez Lopez, R., Reina Zoilo, J.J., Monge, D., Caballero, F., Guillem Porta, V., Aranda Aguilar, E., Carrato Mena, A., Diaz Rubio, E., Garcia Foncillas, J., Feyjoo, M., Camps, C.

Get full text

Evaluation of the sensitivity of RAS mutation detection of the Idylla platform in comparison to the OncoBEAM RAS CRC assay by Vivancos, A, Aranda Aguilar, E, Benavides, M, Elez Fernandez, E, Toledano, M, Alvarez, M, Diaz Rubio, E, Gómez-España, A, Garcia-Barberan, V, Chica-Parrao, M R

Get full text

Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept by González Astorga, B., Salvà Ballabrera, F., Aranda Aguilar, E., Élez Fernández, E., García-Alfonso, P., González Flores, E., Vera García, R., Fernández Montes, A., López Muñoz, A. M., Salud Salvia, A.

“…Colorectal cancer is the second leading cause of cancer-related death worldwide. For metastatic colorectal cancer (mCRC) patients, it is recommended, as…”
Get full text

The quality oncology practice initiative program: Experience in Spain by Lopez Lopez, R., Anton Torres, A., Aranda Aguilar, E., Carrato Mena, A., Constenla Figueiras, M., Cruz Hernandez, J.J., Diaz Rubio, E., Feyjoo, M., Garcia Foncillas, J., Gascon, P.N., Guillem Porta, V., Lugo Cuan, I.S., Rogado, A., Camps, C.

Get full text

Clinical practice evaluation of opioids induced constipation management in oncologic patients: The EIO-50 project by Salvador Bofill, J., Guillem Porta, V., Feyjoo, M., Anton Torres, A., Aranda Aguilar, E., Camps, C., Carrato Mena, A., Constenla Figueiras, M., Cruz Hernandez, J.J., Diaz Rubio, E., Garcia Foncillas, J., Gascon, P.N., Lopez Lopez, R., Soler, B., Escobar, Y.

Get full text

Active study: undetected prevalence and clinical inertia in the treatment of breakthrough cancer pain (BTcP) by Camps Herrero, C., Reina Zoilo, J. J., Monge Martín, D., Caballero Martínez, F., Guillem Porta, V., Aranda Aguilar, E., Carrato Mena, A., Díaz-Rubio García, E., García-Foncillas López, J., Feijóo Saus, M., López López, R.

“…Aims To prove if there is clinical inertia in the identification and treatment of episodes of breakthrough cancer pain (BTcP), comparing actual results from…”
Get full text

Oncologist’s knowledge and implementation of guidelines for breakthrough cancer pain in Spain: CONOCE study by López López, R., Camps Herrero, C., Khosravi-Shahi, P., Guillem Porta, V., Carrato Mena, A., Garcia-Foncillas, J., Cruz Hernández, J. J., Gascón Vilaplana, P., Antón Torres, A., Diaz-Rubio, E., Feyjoo Saus, M., Aranda Aguilar, E.

“…Purpose Breakthrough cancer pain (BTcP) has been shown to be a prevalent and poor prognostic factor for oncologic patients, which remain under diagnosed and…”
Get full text

1839 Association of advanced breast cancer HER-2 positive treated with trastuzumab and Killer cell immunoglobulin-like receptors (KIRs) polymorphisms according to estrogen and progesterone receptor status by Morales-Estevez, C, López-González, J, Manzanares-Martín, B, González-Fernández, R, Ortiz-Morales, M.J, Porras-Quintela, I, Gómez-España, M.A, Moreno-Vega, A, Cano-Osuna, M, Serrano-Blanch, R, De la Haba-Rodríguez, J, Aranda-Aguilar, E

Get full text

Surgical treatment of pulmonary metastases: experience with 40 patients by de la Haba Rodrı́guez, J.Rafael, Algar, J.Algar, Méndez Vidal, M.José, Aranda, I.Barneto, Kindelan, A.Alvarez, Pujol, J.López, Aguilar, E.Aranda

“…Aims: Combinations of surgery and chemotherapy have a favourable impact on survival in the treatment of disseminated neoplastic disease isolated to the lung…”
Get full text

Bevacizumab plus irinotecan in recurrent malignant glioma. Our experience by García Cabezas, S, Serrano Blanch, R, Romeo Olmedo, J, Aranda Aguilar, E, Palacios Eito, A

Get full text

149INTTD CONTRIBUTION TO THE PRECISION ONCOLOGY by Aguilar, E. Aranda

“…Abstract The TTD Group is a Spanish Cooperative Group with 28 years of history investigating and developing protocols in the digestive tumor field to improve…”
Get full text

Ttd Contribution to the Precision Oncology by Aguilar, E. Aranda

Get full text

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer by Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J.H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., Ciardiello, F., D'Hoore, A., Diaz-Rubio, E., Douillard, J.-Y., Ducreux, M., Falcone, A., Grothey, A., Gruenberger, T., Haustermans, K., Heinemann, V., Hoff, P., Köhne, C.-H., Labianca, R., Laurent-Puig, P., Ma, B., Maughan, T., Muro, K., Normanno, N., Österlund, P., Oyen, W.J.G., Papamichael, D., Pentheroudakis, G., Pfeiffer, P., Price, T.J., Punt, C., Ricke, J., Roth, A., Salazar, R., Scheithauer, W., Schmoll, H.J., Tabernero, J., Taïeb, J., Tejpar, S., Wasan, H., Yoshino, T., Zaanan, A., Arnold, D.

“…Colorectal cancer (CRC) is one of the most common malignancies in Western countries. Over the last 20 years, and the last decade in particular, the clinical…”
Get full text

1610P A new updated prognostic index for patients with brain metastases (BM) treated with palliative whole brain radiotherapy (WBRT) in the era of precision oncology: METASNCore project by Paco, P. Flores, López, M.L-H., Lopera, I., Aliaga, A. Vargas, Guevara, G.M., Ruiz, L. Rodríguez, Camús, J.A., González, J.L., Saavedra, E.D. Inga, Gómez, M. Montero, Palacios, A., De la Haba Rodriguez, J., Aguilar, E. Aranda

Get full text

432P Ki67 and progesterone receptor status could be predict sensitivity to cyclin-dependent kinase inhibitor by Berlanga, L. Navarro, Teso, B., Paco, P. Flores, De la Haba Rodriguez, J., Armenta, A., Mora, F., Alonso, B. Rodriguez, Estevez, C. Morales, Quintela, I. Porras, Mauriño, P. Sanchez, Aguilar, E. Aranda

Get full text

560MO Maintenance with 5FU/LV-Aflibercept after induction with FOLFIRI-Aflibercept vs FOLFIRI-Aflibercept until progression in older patients (pts) in 2nd line metastatic colorectal cancer (mCRC): The randomized AFEMA trial by García Alfonso, P., Elez Fernandez, M.E., Soto Alsar, J., Paez, D., Fernandez Montes, A., Grana Suarez, B., Salud, A., Yubero Esteban, A., Gomez España, M.A., Macias Declara, I., Quintero Aldana, G.A., Lopez Lopez, C., Fernandez Rodriguez, T., Gravalos Castro, M.C., González-Flores, E., Guix Arnau, M., García Paredes, B., Reina Zoilo, J.J., Sastre Varela, J., Aranda Aguilar, E.

Get full text

1686TiP Olaparib and durvalumab (MEDI4736) phase II study in patients with metastatic pancreatic cancer and DNA damage repair genes alterations by Macarulla, T., Castet, F., Lobo de Mena, M., Garcia-Carbonero, R., Martinez de Castro, E., Munoz Martin, A.J., Pazo Cid, R.A., Grana Suarez, B., Gallego Plazas, J., Alvarez, R., Ales Diaz, I.C., Gallego Jimenez, I., Laquente, B., Rodriguez, M., García Paredes, B., Cano Osuna, M.T., Ruiz de Mena, I., Fabregat-Franco, C., Espinosa Olarte, P., Aranda Aguilar, E.

Get full text

126P Biliary tract cancer (BTC) characterization on a cohort of patients (pt) from the Spanish RETUD Registry by Lacasta, A., Macarulla, T., Castillo Trujillo, A.O., Herrera Juarez, M.M., Munoz Martin, A.J., Vidal Tocino, R., Fabregat, C., Rodríguez, R.M., Lobo de Mena, M., Peinado, P., Granja Ortega, M., Fernandez Montes, A., Grana Suarez, B., Martinez de Castro, E., Gallego Plazas, J., Vera, R., Ales Diaz, I.C., Ghanem, I., Gallego Jimenez, I., Aranda Aguilar, E.

Get full text

1671P Treatment patterns and efficacy in patients (pt) with pancreatic cancer (PC) from the Spanish RETUD registry by Macarulla, T., Munoz Martin, A.J., Martinez de Castro, E., Castillo Trujillo, A.O., Cano Osuna, M.T., Fabregat, C., Vidal Tocino, R., Gallego Plazas, J., Ghanem, I., Ales Diaz, I.C., Vera, R., Lobo de Mena, M., Adeva Alfonso, J., Melian, M., Gallego Jimenez, I., Laquente, B., Fernandez Montes, A., Peinado Martin, P., Carrato Mena, A., Aranda Aguilar, E.

Get full text

382P Sequential RAS mutation status evaluation in circulating free DNA (cfDNA) in RAS wild type (wt) metastatic colorectal cancer (mCRC) patients (pt) starting first-line (1L) treatment with panitumumab (P) and chemotherapy (CT). PERSEIDA (Idylla Cohort) study by Valladares, M., Safont Aguileria, M.J., González-Flores, E., García Alfonso, P., López Muñoz, A.M., Aranda Aguilar, E., Falco Ferrer, E., Rodriguez-Salas, N., Cirera, L., Llanos-Munoz, M., Aparicio, J., Pimentel, P., Castillo Trujillo, A.O., Salgado Fernandez, M., Salud Salvia, M.A., Vidal Tocino, R., Massuti Sureda, B., Garcia-Carbonero, R., Vicente Conesa, M.A.D.L.A., Lloansi Vila, A.

Get full text